301281.SZ
科源制药
SZSE · C 制造业 · CN
CNY 43.97
−0.20%Year over year
Reported trailing growth
- Revenue
- +4.6%
- EBITDA
- —
- EBIT
- -28.4%
- EPS
- -61.6%
- Free cash flow
- +82.6%
- Operating cash flow
- +226.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -3.5%
- EBITDA
- -14.1%
- EBIT
- -30.9%
- Net income
- -43.4%
- EPS
- -48.8%
- Free cash flow
- +73.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026